Amarin’s Bid to Revive Vascepa Patent at SCOTUS Fails

shot by IP News Shots / 7:01 pm on 22 June, 2021

Amarin Corporation has faced defeat in its bid to get Vascepa patents resurrected after the Supreme Court of the US (SCOTUS) refused to review a decision by the US Court of Appeals for the Federal Circuit (CAFC). The appellate court had found the heart drug patents invalid based on obviousness and ruled in favour of Hikma Pharmaceuticals Plc and other generic makers.

Industry: Pharmaceuticals | Type of IP: Litigations

Read more at Fierce Pharma